TLDR US spot Bitcoin ETFs recorded $1.42 billion in net outflows last week — the third largest weekly exit ever. BlackRock’s IBIT accounted for ~$966 million ofTLDR US spot Bitcoin ETFs recorded $1.42 billion in net outflows last week — the third largest weekly exit ever. BlackRock’s IBIT accounted for ~$966 million of

Bitcoin (BTC) Price: $1.4B Exits Spot ETFs in Third Largest Weekly Outflow on Record

2026/06/01 14:26
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • US spot Bitcoin ETFs recorded $1.42 billion in net outflows last week — the third largest weekly exit ever.
  • BlackRock’s IBIT accounted for ~$966 million of those outflows, with single-day redemptions hitting $448 million.
  • Around 19,021 BTC was sold by ETFs in one week, equal to 42 days of newly mined supply.
  • Bitcoin’s price dropped over 4% in the past week, falling to around $73,000.
  • Macro pressures — including high inflation, rising Treasury yields, and geopolitical tensions — are driving the pullback.

Bitcoin fell over 4% last week, dropping to around $73,000 after briefly reclaiming $82,000 in May. The move lower came as US spot Bitcoin ETFs posted $1.42 billion in net outflows — the third largest weekly total since these products launched, according to available data.

Bitcoin (BTC) PriceBitcoin (BTC) Price

This was the third straight week of heavy redemptions. The three-week running total has now passed $3.5 billion.

BlackRock’s IBIT Leads the Outflows

BlackRock’s IBIT, the largest spot Bitcoin ETF by assets, led the selling. The fund saw roughly $966 million exit in a single week. On its worst single day, redemptions hit $448 million.

When ETF shares are redeemed, the issuer must sell the underlying Bitcoin to cover them. Across all spot ETFs last week, that amounted to roughly 19,021 BTC being offloaded onto the market — the equivalent of 42 days of newly mined supply.

Crypto analyst Ali Charts (@alicharts) highlighted a key level to watch, saying: “I’m watching $72,650 closely on Bitcoin, as the MVRV Pricing Bands continue to identify it as a critical support level. If it fails, the next major demand zone sits between $54,300 and $51,000.” That level sits just below where Bitcoin is currently trading.

What’s Driving the Selling

The macro backdrop is the main driver. Inflation data released in May reduced expectations for a Federal Reserve rate cut. Higher rates make risk-free assets like Treasury bonds more attractive, reducing appetite for volatile assets like Bitcoin.

Geopolitical tension — including a potential re-escalation of the US-Iran conflict — has added pressure. Rising oil prices tied to that tension could push inflation higher still, making rate cuts even less likely.

Analyst AlphaBTC (@mark_cullen) shared a near-term view, saying he’s watching for a push back to $79,000 before a potential move to the low $60,000s later in the summer.

The Crypto Fear & Greed Index remained in “fear” territory throughout the week.

One point of stability: the fact that 19,021 BTC was absorbed by spot market buyers without a sharper price crash suggests some demand remains at current levels.

Bitcoin was trading around $73,000 as of the latest data, with the $72,650 MVRV support level closely watched by analysts.

The post Bitcoin (BTC) Price: $1.4B Exits Spot ETFs in Third Largest Weekly Outflow on Record appeared first on CoinCentral.

Market Opportunity
Bitcoin Logo
Bitcoin Price(BTC)
$72,974.52
$72,974.52$72,974.52
-0.91%
USD
Bitcoin (BTC) Live Price Chart

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage